Trial · NCT07227311
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311, Phase 2, Recruiting, GlaxoSmithKline
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM). Trials, record NCT07227311. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07227311
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- NCT number
- NCT07227311
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 200 participants, estimated
- Lead sponsor
- GlaxoSmithKline
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib
- First posted
- 2025-11-12
- Last updated
- 2026-08-25
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) | Up to approximately 52 months | ORR is defined as the percentage of participants with a confirmed partial response \[PR\] or better (i.e., PR, very good partial response (VGPR), complete response \[CR\], stringent complete response \[sCR\]). Responses will be assessed using International Myeloma Working Group (IMWG) criteria. |
| Secondary | Complete Response Rate (CRR) | Up to approximately 52 months | CRR is defined as the percentage of participants with a confirmed CR or better (i.e., CR, sCR). |
| Secondary | Minimal Residual Disease (MRD) Negativity Rate | Up to approximately 52 months | MRD negativity rate is defined as the percentage of participants who achieve MRD negative status (as assessed by Next generation sequencing \[NGS\] at 10\^-5 threshold) at least once during the time of confirmed CR or better response as per IMWG. |
| Secondary | Duration of Response (DoR) | Up to approximately 52 months | DoR is defined as the time from first documented evidence of PR or better until PD or death due to any cause. |
| Secondary | Number of participants with adverse events (AEs), Serious adverse events (SAEs) by severity | Up to approximately 52 months | |
| Secondary | Number of participants with AEs leading to dose modifications or AEs leading to treatment discontinuation | Up to approximately 52 months | |
| Secondary | Number of Participants With Ocular Findings on Ophthalmic Examination by severity | Up to approximately 52 months | |
| Secondary | Proportion of participants showing concordance between patient-reported ocular symptoms and ophthalmic examination findings | Up to approximately 52 months | Ophthalmic examination findings will be summarized, and contingency table will be constructed to assess the concordance between the results from patient questionnaires (Ocular Surface Disease Index \[OSDI\], PRO-CTCAE ocular scale, and PROSIM-Q) and findings from clinician assessments (CTCAE for eye disorders and Keratopathy and Visual Acuity \[KVA\] grading scale). The proportion of participants showing concordance will be calculated from this analysis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07227311
GET https://conductscience.org/api/trials/v1/NCT07227311/registered